Stifel Reiterates Buy Rating on Crinetics (CRNX)

Stifel analyst Alex Thompson reiterated a Buy rating and $75.00 price target on Crinetics (NASDAQ: CRNX)

The analyst comments "CRNX reported solid updates across the Palsonify and atumelnant franchises. On atumelnant, Cohort 4 and OLE data from the Ph2 CAH study yielded clean safety and supportive evidence for the ongoing Ph3 adult study which features a primary endpoint of both A4 normalization and achievement of physiologic GC doses. Cohort 4 achieved a 67% A4 reduction, in-line with the prior 80mg cohort (70%) despite morning dosing and GC titration. Additionally, patients in the OLE maintained A4 reductions despite GC titration out to at least week 12. Bottom line, Ns are small (8 Cohort 4, 7 OLE), but overall the data support the Ph3 thesis: 2/8 cohort 4 patients achieved both A4 and GC control per management with pre-morning GC A4 measurement (higher bar vs. postGC Ph3 measure). On Palsonify, the 4Q25 pre-report featured a beat >$5MM vs. $3MM and >200 PSFs which should drive 2026 consensus higher, in our view."

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $46.73 yesterday.

You May Also Be Interested In

• Microsoft (MSFT) PT Lowered to $400 at Stifel
• Stifel Reiterates Buy Rating on Crinetics (CRNX)
• Sk Hynix Shares Jump 11% On US Listing Plan, Micron Earnings - Bloomberg